Clinical Trial Update: KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial update for KYSA-7, an anti-CD19 CAR T-cell therapy from Kyverna Therapeutics, studied in adults with refractory primary progres…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Progressive Multiple Sclerosis

Drugs mentioned

• KYSA-7

Snippet

Sponsor: Kyverna Therapeutics | Conditions: Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Status: ACTIVE_NOT_RECRUITING